DNDi needs for future registration of new treatments in Africa.
Abstract
This presentation describes the issues of registration of fexinidazole for human African trypanosomiasis and of paromomycin for visceral leishmaniasis in Africa, with a mention of how nifurtimox-eflornithine combination therapy for the latter disease was dealt with.
Citation
Presentation from DNDi’s Regulatory Workshop - Nairobi, Kenya, 24 June 2009.
Links